Moving the Mercury: Managing IOP via Dual-action Therapy - April 2018

Introduction

This supplement presents the highlights of a roundtable discussion on medical IOP-lowering therapies among a panel of six optometric glaucoma specialists. We come from all over the country, with different patient populations and from a range of institutional settings, including a large university clinic, private practices of differing sizes and a VA hospital. But in all cases, roughly 50% of our patients have glaucoma. In other words, we are intimately familiar with this sight-threatening disease.
- Murray Fingeret, OD